Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

被引:244
作者
Okamoto, Y
Di Patre, PL
Burkhard, C
Horstmann, S
Jourde, B
Fahey, M
Schüler, D
Probst-Hensch, NM
Yasargil, MG
Yonekawa, Y
Lütolf, UM
Kleihues, P
Ohgaki, H
机构
[1] Int Agcy Res Canc, F-69372 Lyon 08, France
[2] Canton Zurich, Canc Registry, CH-8091 Zurich, Switzerland
[3] Coll Med, Dept Neurosurg, Little Rock, AR 72205 USA
[4] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland
[5] Univ Zurich Hosp, Dept Radiol, CH-8091 Zurich, Switzerland
关键词
low-grade diffuse astrocytoma; oligodendroglioma; oligoastrocytoma; population-based study; survival; incidence rate;
D O I
10.1007/s00401-004-0861-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We carried out a population-based study on low-grade diffuse gliomas in the Canton of Zurich, Switzerland (population 1.16 million). From 1980 to 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 122 (12.4%) were low-grade (WHO grade II). The incidence rates adjusted to the World Standard Population, per million population per year, were 2.28 for low-grade diffuse astrocytomas, 0.89 for oligoastrocytomas, and 2.45 for oligodendrogliomas. The survival rate (mean follow-up 7.5+/-4.8 years) was highest for patients with oligodendroglioma (78% at 5 years, 51% at 10 years), followed by those with oligoastrocytoma (70% at 5 years, 49% at 10 years) and fibrillary astrocytoma (65% at 5 years, 31% at 10 years). Survival of patients with gemistocytic astrocytoma was poor, with survival rates of 16% at 5 years and 0% at 10 years. Younger patients (<50 years) survived significantly longer than older patients (>50 years; P=0.013). DNA sequencing, performed in 84% of cases, revealed that TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but were infrequent (13%) in oligodendrogliomas. The presence of TP53 mutations was associated with shorter survival of patients with low-grade diffuse gliomas (log-rank test; P=0.047), but when each histological type was analyzed separately, an association was observed only for oligoastrocytoma (P=0.05). Loss on 1p and 19q were assessed by quantitative microsatellite analysis in 67% of cases. These alterations were frequent in oligodendrogliomas (1p, 57%; 19q, 69%), less common in oligoastrocytomas (1p, 27%; 19q, 45%), rare in fibrillary astrocytomas (1p, 7%; 19q, 7%), and absent in gemistocytic astrocytomas. None of these alterations were predictive of survival. These results establish the frequency of key genetic alterations in low-grade diffuse gliomas at a population-based level. Multivariate Cox's regression analysis indicates that only age and histological type, but not genetic alterations, are significant predictive factors.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 37 条
[1]   P53 IMMUNOREACTIVITY IN ASTROCYTOMAS AND ITS RELATIONSHIP TO SURVIVAL [J].
ALSARRAJ, S ;
BRIDGES, LR .
BRITISH JOURNAL OF NEUROSURGERY, 1995, 9 (02) :143-149
[2]   Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas [J].
Bauman, GS ;
Ino, Y ;
Ueki, K ;
Zlatescu, MC ;
Fisher, BJ ;
Macdonald, DR ;
Stitt, L ;
Louis, DN ;
Cairncross, JG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :825-830
[3]   Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities [J].
Buckner, JC ;
Gesme, D ;
O'Fallon, JR ;
Hammock, JE ;
Stafford, S ;
Brown, PD ;
Hawkins, R ;
Scheithauer, BW ;
Erickson, BJ ;
Levitt, R ;
Shaw, EG ;
Jenkins, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :251-255
[4]   A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma [J].
Burkhard, C ;
Di Patre, PL ;
Schüler, D ;
Schüler, G ;
Yasargil, MG ;
Yonekawa, Y ;
Lütolf, UM ;
Kleihues, P ;
Ohgaki, H .
JOURNAL OF NEUROSURGERY, 2003, 98 (06) :1170-1174
[5]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[6]   PROGNOSTIC IMPLICATIONS OF P53 OVEREXPRESSION IN SUPRATENTORIAL ASTROCYTIC TUMORS [J].
CHOZICK, BS ;
PEZZULLO, JC ;
EPSTEIN, MH ;
FINCH, PW .
NEUROSURGERY, 1994, 35 (05) :831-837
[7]   Randomized trials of radiation therapy in adult low-grade gliomas [J].
Henderson, KH ;
Shaw, EG .
SEMINARS IN RADIATION ONCOLOGY, 2001, 11 (02) :145-151
[8]   Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy [J].
Hilton, DA ;
Love, S ;
Barber, R ;
Ellison, D ;
Sandeman, DR .
NEUROSURGERY, 1998, 42 (04) :724-729
[9]  
IUZZOLINO P, 1994, BRIT J CANCER, V69, P586, DOI 10.1038/bjc.1994.107
[10]  
Kleihues P., 2000, PATHOLOGY GENETICS T